- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
Oncology — Request for Proposals (RFP) Executive Summary
ProblemIMAGING APOPTOSIS IN CANCER PATIENTS
The early evaluation and continuous monitoring of anti-cancer drug efficacy would be markedly enhanced by the ability to assess the entry of tumor cells into apoptosis as a result of drug exposure using non-invasive imaging techniques. While anti-cancer agents can still be developed using traditional measures of efficacy (tumor volume reductions as detected by MR or CT imaging), these measures do not become apparent for a significant time after initiation of chemotherapy. Moreover, some targeted agents induce destruction of tumors that is not manifested as a change in size or volume.
Key Requirements for Successful RFP Bidders
Appropriate investigators would be expected to be cancer researchers at institutions with interest and expertise in the problem, have access to preclinical and clinical imaging tools and have access to cancer patients.
Potential measures of anti-tumor efficacy and apoptosis that are quickly obtainable after the onset of therapeutic intervention. These measures should allow the rapid evaluation of new agents across a spectrum of tumor types even in a Phase 1 setting. A successful tool will facilitate the abandonment of ineffective targets and agents and the rapid progression of effective therapies to Proof of Concept and Phase 3 evaluation.
Time to Solve the Problem
The estimated timeframe is within 3 years. Please provide a best estimate of time in the proposal.
Request for Proposal (RFP) Due Date
All final proposals must be submitted no later than August 31, 2007.
Submitting a Proposal
If you are interested in submitting a proposal to address the above therapeutic area topic, please complete the following informational template and send it to: firstname.lastname@example.org
- Oncology - RFI (PDF)
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.